WO 2004/034996 PCT/US2003/032852

WHAT IS CLAIMED IS:

5

10

15

20

1. A method of treating a patient suffering from substance (particularly alcohol) abuse comprising administering to the patient medication that includes a dose of clozapine, risperidone or both, effective to reduce alcohol use, or a method of making said medication for treating a patient suffering from substance (particularly alcohol) abuse.

- 2. A method of treating a patient suffering from substance (particularly alcohol) abuse comprising administering to the patient medication effective to strongly antagonize α2 andrenergic receptors and to weakly antagonize dopamine D2 receptors, or a method of making said medication for treating a patient suffering from substance (particularly alcohol) abuse.
- 3. A method of treating, a patient suffering from substance (particularly alcohol) abuse comprising administering to the patient medication effective to rectify an alcohol abuse-associated dysfunction in the DA-mediated brain reward circuit, or a method of making said medication for treating a patient suffering from substance (particularly alcohol) abuse.
- 4. The method of any one of claims 1-3 in which the patient is not schizophrenic.
- 5. The method of any one of claims 1-3 in which the medication comprises clozapine.
- 6. The method of any one of claims 2-3 in which the medication comprises:
 - (a) a first component which weakly blocks the D2 receptor; and
 - (b) a second component which strongly blocks $\alpha 2$ receptors.
- 7. The method of claim 6 in which the first component is selected from clozapine, risperidone, olanzapine, quetiapine and ziprasidone.
- 8. The method of claim 6 or 7 in which the second component is idazoxan, or another α2
 receptor antagonist.

WO 2004/034996 PCT/US2003/032852

9. The method of claim 2 in which the medication is formulated as a single dose comprising both the first and the second components.

- 10. The method of claim 2 or 3 in which the medication is characterized by a ratio of α2 blockade: D2 receptor blockade similar to that of clozapine.
- 5 11. The method claim 10 in which the medication is characterized by a ratio of α2C blockade: D2 receptor blockade similar to that of clozapine.
 - 12. The method of claim 6 in which the medication strongly blocks the a2C recepor.
 - 13. A cocktail comprising

5

15

- (c) a first component which weakly blocks the D2 receptor; and
- 10 (d) a strong α2 receptor antagonist.
 - 14. The cocktail of claim 11 in which the first component is selected from clozapine, risperidone, olanzapine, quetiapine and ziprasidone.
 - 15. The cocktail of claim 11 or 12 in which the second component is idazoxan, or another α2 receptor antagonist.
- 15 16. The cocktail of claim 11 or 12 in which the cocktail is characterized by strong blockade of the α2C receptor.
 - 17. The cocktail of claim 11 or claim 12 in which the cocktail is characterized by a ratio of α2 blockade: D2 receptor blockade similar to that of clozapine.
- 18. The method claim 10 in which the cocktail is characterized by a ratio of α2C blockade:
 D2 receptor blockade similar to that of clozapine.